MedTrace Logo

Alpha Lipoic Acid in Ulcerative Colitis

NCT06067698 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-02-06

No results posted yet for this study

Summary

This study aims at evaluating the efficacy and safety of alpha-lipoic acid as adjuvant therapy to mesalamine in patients with mild to moderate ulcerative colitis due to its effect as anti-oxidant and anti-inflammatory drug which can help to improve disease.

Conditions

Interventions

DRUG

"Mesalamine" and "alpha-lipoic acid"

Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months

DRUG

"Mesalamine" and "Placebo"

Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2025-04-01
Completion
2025-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06067698 on ClinicalTrials.gov